A Targeted Methylation–Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease

Brandon A. Mahal; Matthew Margolis; Earl Hubbell; Cheng Chen; Jeffrey M. Venstrom; John Abran; Jordan J. Kartlitz; Alexander W. Wyatt; Eric A. Klein

doi:10.1200/PO.24.00269

Back

A Targeted Methylation–Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease

Journal article

Peer reviewed

A Targeted Methylation–Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease

Brandon A. Mahal, Matthew Margolis, Earl Hubbell, Cheng Chen, Jeffrey M. Venstrom, John Abran, Jordan J. Kartlitz, Alexander W. Wyatt and Eric A. Klein

JCO precision oncology, Vol.8(8), p.e2400269

2024-08

DOI: https://doi.org/10.1200/PO.24.00269

PMID: 39208374

Appears in Miller School of Medicine - Latest Publications

Metrics

1 Record Views

See more details

Details

Title: A Targeted Methylation–Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease
Creators: Brandon A. Mahal - Sylvester Comprehensive Cancer Center
Matthew Margolis - Grail
Earl Hubbell - Grail
Cheng Chen - Grail
Jeffrey M. Venstrom - Grail
John Abran - Grail
Jordan J. Kartlitz - Grail
Alexander W. Wyatt - University of British Columbia
Eric A. Klein - Grail
Publication Details: JCO precision oncology, Vol.8(8), p.e2400269
Grant note: Citrus Health Group, Inc. CRC Health Group (100007177)
Academic Unit: Miller School of Medicine; UMMG Dept of Radiation Oncology
Language: English
Resource Type: Journal article
PMID: 39208374
Record Identifier: 991032795928902976